Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2022

View Archived Issues

New murine model of AIH developed using a human liver protein

Science & Technology Development Fund Authority presents new antiviral nucleosides

New DDR1 and/or DDR2 inhibitors identified at Galapagos

PI3K-delta inhibitors patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Sichuan Haisco Pharmaceutical discovers polymerase basic protein 2 inhibitors

Beijing Findcure Biosciences divulges new tyrosine-protein kinase receptor UFO inhibitors

SLAMF3 and SLAMF4 targeting for treating hematopoietic cancers

HMGB1 restricts EPO signaling, contributing to anemia of inflammation

CCR4 mediates postoperative pain through skin dendritic cells

Sarepta and GenEdit report progress under collaboration for neuromuscular diseases

Catalog of protein isoforms in blood cells can predict organ rejection

Skye reports data on SBI-100 ophthalmic nanoemulsion in preclinical glaucoma model

Neuronal PFKFB3 upregulation involved in ceroid lipofuscinosis

Discovery of novel ATX inhibitor with promising antifibrosis efficacy in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...